Methylprednisolone Acetate

Summary

Methylprednisolone Acetate (CHEMBL1364144) is an approved small-molecule anti-inflammatory drug; indicated across 22 conditions including rheumatoid arthritis and frozen shoulder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 22 conditions
• Clinical trials: 20
• Chemistry: 416.5 Da · C24H32O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1364144
Name	Methylprednisolone Acetate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5877
ChEBI	CHEBI:6889
Molecular formula	C24H32O6
Molecular weight	416.5
InChIKey	PLBHSZGDDKCEHR-LFYFAGGJSA-N

SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)C)O

IUPAC name: [2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate

ChEBI definition: An acetate ester resulting from the formal condensation of the 21-hydroxy function of 6α-methylprednisolone compound with acetic acid.

Pharmacological roles (ChEBI): anti-inflammatory drug.

Also known as: Depo-medrol, Depo-medrone, M-predrol, Medrol acetate, Methyl prednisolone acetate, Methylprednisolone acetate, Neo-medrone, NSC-48985, SID50085428, METHYLPREDNISOLONE ACETATE, 6alpha-METHYLPREDNISOLONE ACETATE, SID144205275

Patent coverage: 4,503 distinct patent families (13,435 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Androgen receptor, Prothrombin, Progesterone receptor.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	5.52	AC50	3030	nM	CHEMBL_ACT_25204634
AR	5.49	AC50	3270	nM	CHEMBL_ACT_25203701

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

13 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
rheumatoid arthritis	4	MONDO:0008383	EFO:0000685
frozen shoulder	4	MONDO:0006763	EFO:1000941
leukemia	4	MONDO:0005059	EFO:0000565
lymphoma	4	MONDO:0005062	EFO:0000574
brain neoplasm	4	MONDO:0021211	EFO:0003833
nephrotic syndrome	4	MONDO:0005377	EFO:0004255
type III hypersensitivity disease	4	MONDO:0007004	EFO:1001222
uveitis	4	MONDO:0020283	EFO:1001231
infectious disease	4	MONDO:0005550	MONDO:0002041
anemia	4	MONDO:0002280	MONDO:0002280
dermatitis	4	MONDO:0002406	MONDO:0002406
asthma	4	MONDO:0004979	MONDO:0004979
osteoarthritis	4	MONDO:0005178	MONDO:0005178

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
carpal tunnel syndrome	3	MONDO:0007275	EFO:0004143
gout	2	MONDO:0005393	EFO:0004274
shoulder impingement syndrome	2	MONDO:0006968	EFO:1001178
epicondylitis	2	MONDO:0001875	EFO:1001896
optic neuritis	2	MONDO:0005885	EFO:0007405

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
Not specified	8
PHASE4	5
PHASE3	4
PHASE2	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05929755	PHASE4	RECRUITING	Depo-Medrol on Psoas After LLIF
NCT01652495	PHASE4	COMPLETED	Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection
NCT02038452	PHASE4	COMPLETED	Injection Versus Splinting in Carpal Tunnel Syndrome
NCT02403856	PHASE4	COMPLETED	Efficacy and Tolerance of Ultrasound-guided Needling and Lavage of Calcific Tendinitis of the Rotator Cuff Performed With or Without Subacromial Corticosteroid Injection
NCT02847494	PHASE4	COMPLETED	Corticosteroids for Acute Migraine in the Emergency Department
NCT05058287	PHASE3	RECRUITING	Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression
NCT06532318	PHASE3	NOT_YET_RECRUITING	Comparative Study Between Platelet Rich Plasma and Steroid Injection in Trigger Finger Treatment
NCT07371572	PHASE3	RECRUITING	The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis
NCT03794505	PHASE3	COMPLETED	Quality of Life and Pain With Infiltration or Suprascapular Nerve Block in Glenohumeral Arthirtis
NCT03913702	PHASE2	TERMINATED	Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement
NCT06790615	PHASE1/PHASE2	COMPLETED	Comparison of Thread Technique Versus Aspiration Plus Steroid Injection for Wrist Ganglion Recurrence
NCT04051203	PHASE1	COMPLETED	Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia
NCT03924791	Not specified	RECRUITING	Transforaminal Epidural Injection in Acute Sciatica
NCT00492973	Not specified	COMPLETED	Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?
NCT00656110	Not specified	UNKNOWN	Neuroma Injections to Treat Restless Legs Syndrome - RCT
NCT00887003	Not specified	COMPLETED	Epidural Study of Patients With Chronic Lower Back Pain
NCT01397552	Not specified	TERMINATED	Dexamethasone Versus Depo Medrol in Lumbar Epidurals
NCT02539394	Not specified	COMPLETED	Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion
NCT03742466	Not specified	COMPLETED	Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients
NCT04593706	Not specified	UNKNOWN	Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).